Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

865.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 670
Open 865.00
Bid (Size) 859.01 (1)
Ask (Size) 864.00 (2)
Prev. Close 865.00
Today's Range 865.00 - 865.00
52wk Range 711.40 - 972.53
Shares Outstanding N/A
Dividend Yield 0.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Healthcare And Biotech Playbook As Disruption Gathers Force
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities

Performance

YTD
+11.17%
+11.17%
1 Month
+8.47%
+8.47%
3 Month
+5.63%
+5.63%
6 Month
-4.74%
-4.74%
1 Year
+17.33%
+17.33%

More News

Read More
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Via Benzinga
5 ETFs That Beat Market Turmoil With Gains Last Week
Via Benzinga
Topics ETFs Economy
Exposures Interest Rates
2 Growth Stocks to Buy Hand Over Fist in February
Via The Motley Fool
Is Novo Nordisk Stock a Buy Now?
Via The Motley Fool
Looking Into Eli Lilly's Recent Short Interest
Via Benzinga
Market Monitor February 6th
Via Chartmill
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Via MarketBeat
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
Via Stocktwits
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
How To Ride The Market’s “Great Risk Rollercoaster”
Via Talk Markets
Topics ETFs Stocks / Equities
A Closer Look at Eli Lilly's Options Market Dynamics
Via Benzinga
Why Eli Lilly Stock Popped on Thursday
Via The Motley Fool
Magnificent Seven Slip, Inflation Fears Grip Consumers, Gold Hits Record Highs: This Week In The Markets
Via Benzinga
Topics Economy
Exposures Interest Rates
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Via Investor's Business Daily
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Via Benzinga
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Via Stocktwits
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
Trump Focused On 10-Year Yield And Not On The Fed, Slower AI Growth Fears Weigh On Arm Stock
Via Benzinga
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Interest Rates Political
The 9 Best Stocks to Buy Now in February (2025)
Via The Motley Fool
In 2025, the pharmaceutical industry is ripe for M&A
Via Equities.com
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat
Via Stocktwits
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
Via Investor's Business Daily
Exposures Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.